Presentation is loading. Please wait.

Presentation is loading. Please wait.

Influence of low-glucose peritoneal dialysis on serum lipids and apolipoproteins in the IMPENDIA/EDEN trials  Allan D. Sniderman, MD, James A. Sloand,

Published byBasil Knight Modified over 5 years ago

Similar presentations

Presentation on theme: "Influence of low-glucose peritoneal dialysis on serum lipids and apolipoproteins in the IMPENDIA/EDEN trials  Allan D. Sniderman, MD, James A. Sloand,"— Presentation transcript:

1 Influence of low-glucose peritoneal dialysis on serum lipids and apolipoproteins in the IMPENDIA/EDEN trials  Allan D. Sniderman, MD, James A. Sloand, MD, FASN, Philip K.T. Li, MD, FRCP, Ken Story, MS, Joanne M. Bargman, MD, FRCPC  Journal of Clinical Lipidology  Volume 8, Issue 4, Pages (July 2014) DOI: /j.jacl Copyright © 2014 National Lipid Association Terms and Conditions

2 Figure 1 Difference in mean change from baseline between control and low-glucose groups at the 6-month visit. ApoA1, apolipoprotein A1; apoB, apolipoprotein B; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein (a); Total-C, total cholesterol; TG, triglyceride; VLDL-C, very low-density lipoprotein cholesterol. *P = .030; **P = .003; ***P = .002. Journal of Clinical Lipidology 2014 8, DOI: ( /j.jacl ) Copyright © 2014 National Lipid Association Terms and Conditions

3 Figure 2 Statin use during the course of the study. White bars, control; black bars, low glucose. Journal of Clinical Lipidology 2014 8, DOI: ( /j.jacl ) Copyright © 2014 National Lipid Association Terms and Conditions

4 Figure 3 Change in apolipoprotein B in patients (A) not prescribed lipid-lowering medications (P = .023 at 3 months and P = .010 at 6 months) or (B) without a change in dose of lipid-lowering medication (P = .25 at 3 months and P = .24 at 6 months) during the course of the study. apoB, apolipoprotein (B); black bars, low glucose; white bars, control. Journal of Clinical Lipidology 2014 8, DOI: ( /j.jacl ) Copyright © 2014 National Lipid Association Terms and Conditions

5 Figure 4 Mean change in apolipoprotein B at 3 months and 6 months according to the baseline quartile. Shading shows quartiles of apoB range. apoB, apolipoprotein (B); white, Q1 and Q2 (39–<89 mg/dL); gray, Q3 (89–<110 mg/dL); black, Q4 (110–182 mg/dL). Journal of Clinical Lipidology 2014 8, DOI: ( /j.jacl ) Copyright © 2014 National Lipid Association Terms and Conditions

Download ppt "Influence of low-glucose peritoneal dialysis on serum lipids and apolipoproteins in the IMPENDIA/EDEN trials  Allan D. Sniderman, MD, James A. Sloand,"

Similar presentations

Interrupting bile-acid handling and lipid and glucose control: Effects of colesevelam on glucose levels  Michael H. Davidson, MD  Journal of Clinical.

Interrupting bile-acid handling and lipid and glucose control: Effects of colesevelam on glucose levels  Michael H. Davidson, MD  Journal of Clinical.
Lipid abnormalities in foreign-born and US-born patients in a medical group  Jawali Jaranilla, MD, MPH, Terese DeFor, MS, Gabriela Vazquez Benitez, PhD,

Lipid abnormalities in foreign-born and US-born patients in a medical group  Jawali Jaranilla, MD, MPH, Terese DeFor, MS, Gabriela Vazquez Benitez, PhD,
Lipoprotein(a), Cardiovascular Disease, and Contemporary Management

Lipoprotein(a), Cardiovascular Disease, and Contemporary Management
Patient and Physician Perspectives on Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels†  Eli.

Patient and Physician Perspectives on Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels†  Eli.
A Blend of Sesame and Rice Bran Oils Lowers Hyperglycemia and Improves the Lipids  Sankar Devarajan, PhD, Biprabuddha Chatterjee, MSc, Hidenori Urata,

A Blend of Sesame and Rice Bran Oils Lowers Hyperglycemia and Improves the Lipids  Sankar Devarajan, PhD, Biprabuddha Chatterjee, MSc, Hidenori Urata,
Charles R. Harper, MD, Terry A. Jacobson, MD  Mayo Clinic Proceedings 

Charles R. Harper, MD, Terry A. Jacobson, MD  Mayo Clinic Proceedings 
Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial.

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial.
A Blend of Sesame and Rice Bran Oils Lowers Hyperglycemia and Improves the Lipids  Sankar Devarajan, PhD, Biprabuddha Chatterjee, MSc, Hidenori Urata,

A Blend of Sesame and Rice Bran Oils Lowers Hyperglycemia and Improves the Lipids  Sankar Devarajan, PhD, Biprabuddha Chatterjee, MSc, Hidenori Urata,
Purified palmitoleic acid for the reduction of high-sensitivity C-reactive protein and serum lipids: A double-blinded, randomized, placebo controlled.

Purified palmitoleic acid for the reduction of high-sensitivity C-reactive protein and serum lipids: A double-blinded, randomized, placebo controlled.
Omega-3 Fatty Acids for Cardioprotection

Omega-3 Fatty Acids for Cardioprotection
Martin W. Schoen, MD, MPH, Joanne Salas, MPH, Jeffrey F

Martin W. Schoen, MD, MPH, Joanne Salas, MPH, Jeffrey F
Charles R. Harper, MD, Terry A. Jacobson, MD  Mayo Clinic Proceedings 

Charles R. Harper, MD, Terry A. Jacobson, MD  Mayo Clinic Proceedings 
Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients  Evan Stein, MD, Harold Bays, MD, Michael Koren,

Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients  Evan Stein, MD, Harold Bays, MD, Michael Koren,
Association of triglyceride-to-high density lipoprotein cholesterol ratio to cardiorespiratory fitness in men  Gloria Lena Vega, PhD, Scott M. Grundy,

Association of triglyceride-to-high density lipoprotein cholesterol ratio to cardiorespiratory fitness in men  Gloria Lena Vega, PhD, Scott M. Grundy,
Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management of hypercholesterolemia  Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA,

Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management of hypercholesterolemia  Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA,
Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial  Erik S.G. Stroes, MD, PhD, Andrey.

Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial  Erik S.G. Stroes, MD, PhD, Andrey.
Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with.

Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with.
Sebelipase alfa improves atherogenic biomarkers in adults and children with lysosomal acid lipase deficiency  Don P. Wilson, MD, FNLA, Mark Friedman,

Sebelipase alfa improves atherogenic biomarkers in adults and children with lysosomal acid lipase deficiency  Don P. Wilson, MD, FNLA, Mark Friedman,
Apolipoprotein E-containing high-density lipoprotein (HDL) modifies the impact of cholesterol-overloaded HDL on incident coronary heart disease risk:

Apolipoprotein E-containing high-density lipoprotein (HDL) modifies the impact of cholesterol-overloaded HDL on incident coronary heart disease risk:

Similar presentations

Ads by Google